Pfizer-BioNTech COVID-19 (12y+) Bivalent Vaccine PF Side Effects
Generic name: sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine
Note: This document contains side effect information about sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine. Some dosage forms listed on this page may not apply to the brand name Pfizer-BioNTech COVID-19 (12y+) Bivalent Vaccine PF.
Applies to sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine: intramuscular suspension.
General
The most commonly reported side effects included injection site pain, fatigue, headache, and myalgia.[Ref]
Cardiovascular
Postmarketing reports: Myocarditis, pericarditis[Ref]
Dermatologic
Postmarketing reports: Angioedema, erythema multiforme, pruritus, skin rash, urticaria[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (up to 13.7%)
Common (1% to 10%): Vomiting
Uncommon (0.1% to 1%): Nausea[Ref]
Hematologic
Uncommon (0.1% to 1%): Lymphadenopathy[Ref]
Hypersensitivity
Postmarketing reports: Anaphylaxis, severe allergic reactions[Ref]
Local
Very common (10% or more): Injection site pain (up to 79.4%)
Common (1% to 10%): Injection site redness, injection site swelling[Ref]
Metabolic
Uncommon (0.1% to 1%): Decreased appetite[Ref]
Musculoskeletal
Very common (10% or more): Myalgia (up to 33.7%), new/worsened muscle pain (up to 31.4%), arthralgia (up to 23.5%), new/worsened joint pain (up to 16.7%)
Common (1% to 10%): Extremity pain (arm)
Frequency not reported: Joint pain, muscle pain[Ref]
Nervous system
Very common (10% or more): Headache (up to 47.6%)
Frequency not reported: Bell's palsy, facial paralysis
Postmarketing reports: Dizziness, hypoesthesia, paresthesia[Ref]
Bell's palsy was mild to moderate in severity, began 3 to 48 days after the last dose, included facial paralysis and facial paresis, and typically lasted 3 to 68 days. This side effect was reported in 4 participants who received the vaccine and 2 patients who received a placebo, but a causal relationship to the vaccine could not be made.[Ref]
Other
Very common (10% or more): Fatigue (up to 64.3%), use of antipyretic/pain medication (up to 46.7%), chills (up to 31.6%)
Common (1% to 10%): Fever (at least 38C)
Uncommon (0.1% to 1%): Malaise[Ref]
More about Pfizer-BioNTech COVID-19 (12y+) Bivalent Vaccine PF (sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine)
References
1. Product Information. Comirnaty Original and Omicron BA 4-BA 5 (SARS-CoV-2 (famtozinameran and tozinameran 12y+) bivalent booster). Pfizer Canada Inc. 2022.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.